Monday, May 19, 2014

Searching For A Follow-Up Act, Samsung Turns To Drugs

Samsung has set up a biotech subsidiary that is starting to produce biosimilars, or follow-on versions of expensive biotech drugs that are facing expiring patents.



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.